Follicular Lymphoma
📧 Sign up to get email alerts when something new happens for Follicular Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2020-03-11Clinical Trial Update: A Clinical Trial of Metformin in the Maintenance of Non-Hodgkin's Lymphoma Patients [Phase 2]
A Phase 2 clinical trial evaluating metformin for maintenance therapy in non-Hodgkin lymphoma patients is listed, with unclear status.
-
CLINICAL_TRIALS trial_result · 2020-01-29Clinical Trial Update: To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan [Phase 3]
Phase 3 trial update evaluating equivalence in pharmacokinetics and noninferiority of efficacy for CT-P10 versus Rituxan in lymphoma (follic…
-
CLINICAL_TRIALS trial_result · 2020-01-06Clinical Trial Update: Rituximab and Involved Field Radiotherapy in Early Stage Follicular Lymphoma [Phase 2]
Phase 2 clinical trial update evaluating rituximab with involved field radiotherapy in early-stage follicular lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2019-12-30Clinical Trial Update: A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating atezolizumab with obinutuzumab and lenalidomide for relapsed or refractory follicular lymphoma has completed with…
-
FDA approval · 2019-11-21FDA Approved: TREANDA — Supplemental Application (Cephalon, LLC)
The FDA approved a supplemental application for TREANDA (bendamustine hydrochloride) submitted by Cephalon, LLC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-11-05Clinical Trial Update: A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) [Phase 1, Phase 2]
Phase 1/2 trial assessing safety and efficacy of obinutuzumab, polatuzumab vedotin, and atezolizumab in relapsed/refractory follicular lymph…
-
CLINICAL_TRIALS trial_result · 2019-10-29Clinical Trial Update: Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refractory Follicular Lymphoma [Phase 2]
Phase 2 study of oral ixazomib in adults with relapsed/refractory follicular lymphoma has completed with results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-10-15Clinical Trial Update: Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma [Phase 2]
A Phase II study evaluating fractionated 90Y ibritumomab tiuxetan (Zevalin) as initial therapy for follicular lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2019-10-11Clinical Trial Update: Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer [Phase 2]
Phase 2 clinical trial update on donor umbilical cord blood transplant for hematologic cancers; status completed with results posted.
-
FDA label_change · 2019-10-08FDA Approved: BENDEKA — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for Bendeka (bendamustine hydrochloride) by Teva Pharmaceuticals to update its labeling.
-
CLINICAL_TRIALS trial_result · 2019-08-28Clinical Trial Update: Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL [Phase 2]
Phase 2 trial update for rituximab, yttrium Y-90 ibritumomab tiuxetan in relapsed follicular non-Hodgkin lymphoma (stages II-IV).
-
CLINICAL_TRIALS trial_result · 2019-08-28Clinical Trial Update: Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial evaluating a regimen of fludarabine, mitoxantrone, and rituximab in relapsed or primary failing advanced follicular lymphoma h…
-
CLINICAL_TRIALS trial_result · 2019-08-13Clinical Trial Update: Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma) [Phase 3]
Phase 3 trial update for rituximab plus lenalidomide in relapsed/refractory indolent non-Hodgkin lymphoma (follicular lymphoma and marginal …
-
FDA approval · 2019-07-23FDA Approved: RUXIENCE — Original Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved Ruxience (rituximab-pvvr) from Pfizer as a biosimilar to rituximab, under an original application; the approval covers multiple…
-
CLINICAL_TRIALS trial_result · 2019-07-08Clinical Trial Update: R2 in the Treatment of Follicular Lymphoma [Phase 2]
Phase 2 clinical trial update for R2 in the treatment of Follicular Lymphoma.
-
CLINICAL_TRIALS trial_result · 2019-06-27Clinical Trial Update: A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas [Phase 1, Phase 2]
A multi-center phase 1/2 trial evaluating ibrutinib combined with MEDI4736 in relapsed or refractory lymphomas has completed enrollment with…
-
CLINICAL_TRIALS trial_result · 2019-06-13Clinical Trial Update: A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) [Phase 1, Phase 2]
Phase 1/2 trial evaluating atezolizumab with obinutuzumab-based regimens in follicular lymphoma and diffuse large B-cell lymphoma has been c…
-
FDA approval · 2019-05-23FDA Approved: TRUXIMA — Supplemental Application (Cephalon, Inc.)
FDA approved a supplemental application for TRUXIMA (rituximab-ABBS) submitted by Cephalon, Inc.
-
CLINICAL_TRIALS trial_result · 2019-04-17Clinical Trial Update: Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating tandem CAR T cells targeting CD19 and CD22 for relapsed or chemotherapy-refractory B-cell malignancies.
-
CLINICAL_TRIALS trial_result · 2019-04-16Clinical Trial Update: Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma [Phase 2]
Phase 2 trial evaluating ibrutinib in combination with rituximab in previously untreated follicular lymphoma shows completed status with pos…
-
CLINICAL_TRIALS trial_result · 2019-02-27Clinical Trial Update: Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating memory-enriched CAR-T cell therapy for various recurrent B cell lymphomas, including diffuse large B c…
-
CLINICAL_TRIALS trial_result · 2019-01-28Clinical Trial Update: Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas [Phase 1]
Phase 1 study of alisertib plus romidepsin in relapsed or refractory B-cell and T-cell lymphomas has completed.
-
CLINICAL_TRIALS trial_result · 2019-01-23Clinical Trial Update: Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) [Phase 2]
Phase 2 study evaluating novel approaches to prevent graft-versus-host disease after allogeneic hematopoietic cell transplantation, with res…
-
CLINICAL_TRIALS trial_result · 2019-01-10Clinical Trial Update: Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma [Phase 2]
Phase 2 trial evaluating ofatumumab plus bendamustine hydrochloride, with or without bortezomib, in untreated follicular lymphoma; the study…
-
CLINICAL_TRIALS trial_result · 2019-01-08Clinical Trial Update: Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma [Phase 2]
Phase 2 trial assessing denintuzumab mafodotin (SGN-CD19A) with RCHOP/RCHP vs RCHOP alone in diffuse large B-cell lymphoma and follicular ly…